Background {#Sec1}
==========

Canine leishmaniosis (CanL) is a significant zoonotic disease in Mediterranean region and is caused by the kinetoplastid parasite *Leishmania infantum* that is transmitted by sand flies vectors belonging to the *Phlebotomus* genus \[[@CR1]\]. Often vector-borne pathogens (VBP) such as *Anaplasma platys, Ehrlichia canis*, *Dirofilaria immitis*, *Hepatozoon canis* and *Babesia vogeli* concurrently infect dogs which have clinical leishmaniosis (ClinL) despite being transmitted by vectors different than these for *L. infantum* \[[@CR2]--[@CR4]\]. Such co-infections can result in an unexpected incubation time, atypical clinical sings, more severe clinicopathological abnormalities and worse prognosis for the dogs with CanL, compared with dogs that have CanL alone \[[@CR2], [@CR3], [@CR5]\]. Furthermore, a recent PCR-based case-control study found that dogs with ClinL are in higher risk to be co-infected with *E. canis* compared to healthy matched controls \[[@CR6]\]. Additional information on co-infections in ClinL cases with VBP, as assessed by serology in case-control studies, is required.

The aim of this study was to examine if dogs with ClinL are more likely to be exposed to *A. phagocytophilum*/*A. platys*, *B. burgdorferi* and *E. canis*/*Ehrlichia ewingii*, or infected for *D. immitis* than clinically healthy controls.

Results {#Sec2}
=======

Serum was available in 47 dogs with ClinL and 87 dog controls that were included in this study. The age of these 134 dogs ranged from 1 up to 12 years (median 4 years, interquartile range 3 years) and 98 (73%) were pedigree including Cocker spaniel, Segugio Italiano, Beagle, German Shepherd and other breeds (Additional file [1](#MOESM1){ref-type="media"}).

In the ClinL group, anti-*A*. *phagocytophilum*/*A*. *platys* antibodies were detected in 5 (10.6%), anti-*E. canis*/*E*. *ewingii* antibodies in 17 (36.2%) and antigen for *D*. *immitis* in 2 (4.3%) dogs. Of the 87 control dogs, *anti-A*. *phagocytophilum*/*A*. *platys* antibodies were detected in 2 (2.3%) and anti-*E. canis*/*E*. *ewingii* antibodies in 14 (16.1%). No anti-*B*. *burgdorferi* antibody tests were positive (Fig. [1](#Fig1){ref-type="fig"}). Table [1](#Tab1){ref-type="table"} summarizes the demographic characteristics and the serology findings. The two dogs with *D*. *immitis* antigens underwent microfilaria PCR specification which was positive for *A. reconditum* and negative for *D*. *immitis* for both cases. Fig. 1Comparison of VBP percentages detected by serology between dogs with ClinL (*n* = 47) and healthy control dogs (*n* = 87). *Abbreviations: VBP, vector-borne pathogen; ClinL, clinical leishmaniosis; E. canis, Ehrlichia canis; E. ewingii, Ehrlichia ewingii; D. immitis, Dirofilaria immitis; A. phagocytophilum, Anaplasma phagocytophilum; A. platys. Anaplasma platys* Table 1Demographic characteristics of the study dog groups and serology results for the VBPs tested. All dogs tested negative for *Borrelia burgdorferi* antibodiesCharacteristicNo. of cases\
ClinL (%) (*n* = 47)No. of Control (%) (*n* = 87)Age in years Median3.04.1 Interquartile range3.33.0Sex Male23 (49)47 (54) Female24 (51)40 (46)Lifestyle Outdoors34 (72)65 (75) Mainly indoors13 (28)22 (25)Ectoparasitic prevention Used16 (34)36 (41) Not used31 (66)51 (59)Breed Pedigree33 (70)65 (75) Crossbreed14 (30)22 (25)*E. canis/E. ewingii* Positive17 (36)14 (16) Negative30 (64)73 (84)*A. phagocytophilum/A. platys* Positive5 (10)2 (2) Negative42 (90)85 (98)*D*. *immitis* Positive2 (4)0 (0) Negative45 (96)87 (100)*Abbreviations*: *VBP* Vector-borne pathogen, *ClinL* Clinical leishmaniosis, *E. canis Ehrlichia canis*, *E. ewingii Ehrlichia ewingii*, *D. immitis Dirofilaria immitis*, *A. phagocytophilum Anaplasma phagocytophilum*, *A. platys. Anaplasma platys*

ClinL was significantly associated with anti-*E. canis*/*E*. *ewingii* antibodies \[odds ratio (OR) = 2.9, 95% confidence interval (CI): 1.3--6.7, *P* = 0.010\], compared to healthy controls using multivariable logistic regression. The presence of *anti-A*. *phagocytophilum*/*A*. *platys* antibodies was initially associated significantly with ClinL compared to controls using univariable analysis (OR = 5.1, 95% CI: 0.9--27.2, *P* = 0.038) but this association was not maintained during multivariable logistic regression analysis. The numbers of *D*. *immitis* were very low hindering any further statistical analysis. Age, breed, sex, lifestyle, and use of ectoparasitic prevention were not statistically different between the ClinL and the control dogs.

Two associations were identified based on SEM (Fig. [2](#Fig2){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). It was more likely for dogs with ClinL be *E. canis*/*E*. *ewingii* seropositive and dogs seropositive for *E. canis*/*E*. *ewingii* are more likely to have be infected with *E. canis* based on PCR. A trend was identified between dogs with ClinL and *A*. *phagocytophilum*/*A*. *platys* seropositive. Fig. 2Structural equation model showing predictors of vector-borne serological exposure status (except ClinL), and pathogen covariance (including ClinL), in domestic dogs. Values represent standardised coefficients among variables. Single headed arrows represent directional/causal relationships and double headed arrows covariance relationships among pathogens. For image clarity the serological status is in yellow boxes and the coefficients of host characteristics predicting pathogens are listed next to each host characteristic. The covariances *E. canis*, *A. platys*, *Hepatozoon* spp. and *M. haemocanis* were PCR-based diagnosed. In all cases, except age, variables are binomial (0 or 1) with 1 equal to male, outside, ectoparasitic prevention use, pedigree and positive pathogen status. Standardised coefficients with significant relationships of *P* ≤ 0.05 (also see Table [2](#Tab2){ref-type="table"}) are denoted in bold. *Abbreviations: ClinL, clinical leishmaniosis; E. canis, Ehrlichia canis; E. ewingii, Ehrlichia ewingii; A. phagocytophilum, Anaplasma phagocytophilum; A. platys. Anaplasma platys; M. haemocanis, Mycoplasma haemocanis* Table 2Structural equation model statistical output showing host characteristics predicting serological exposure status for co-infecting pathogens (except ClinL), and the covariance among pathogens (including ClinL), in domestic dogs. The covariances *E. canis*, *A. platys*, *Hepatozoon* spp. and *M. haemocanis* were PCR based diagnosed. In all cases, except age, variables are binomial (0 or 1) with 1 equal to male, outside, ectoparasites controlled, pedigree and positive pathogen statusStandardised coefficient/covariancez-value*P*-value*E. canis/E. ewingii* serology Age−0.081−0.9080.364 Sex−0.015− 0.1430.886 Lifestyle0.0590.5150.606 Ectoparasite prevention−0.041− 0.3360.737 Pedigree0.0150.1420.887*A. phagocytophilum/A. platys* serology Age−0.035−0.4150.678 Sex0.0140.1030.918 Lifestyle−0.037− 0.3630.717 Ectoparasite prevention−0.162−1.5320.126 Pedigree−0.111−0.8610.389Covariances *E. canis/E. ewingii* \~\~ ClinL0.2292.453**0.014** *A. phagocytophilum/A. platys* \~\~ ClinL0.1831.6540.098\* *E. canis/E. ewingii* \~\~ *A. phagocytophilum/A. platys*0.1801.4430.149 *E. canis/E. ewingii* \~\~ *E. canis*0.3172.164**0.030** *E. canis/E. ewingii* \~\~ *A. platys*0.0090.0920.926 *E. canis/E. ewingii* \~\~ *Hepatozoon* spp.0.0680.7470.455 *E. canis/E. ewingii* \~\~ *M. haemocanis*0.0991.0150.310 *A. phagocytophilum/A. platys* \~\~ *E. canis*−0.015−0.3580.721 *A. phagocytophilum/A. platys* \~\~ *A. platys*0.3491.2900.197 *A. phagocytophilum/A. platys* \~\~ *Hepatozoon* spp.−0.106−1.1670.243 *A. phagocytophilum/A. platys* \~\~ *M. haemocanis*0.000−0.0050.996Significant relationships (*P* \< 0.05) denoted by bold font and trending relationships (*P* \< 0.1) denoted by \**Abbreviations*: *VBP* Vector-borne pathogen, *ClinL* Clinical leishmaniosis, *E. canis Ehrlichia canis*, *E. ewingii Ehrlichia ewingii*, *A. phagocytophilum Anaplasma phagocytophilum*, *A. platys. Anaplasma platys*, *M. haemocanis Mycoplasma haemocanis*

Discussion {#Sec3}
==========

The findings from this serology study are in agreement with previous studies \[[@CR3], [@CR7]\] and further support the findings from the initial PCR based study, using a fairly similar cohort of samples, in which it was demonstrated that it is 12 times more likely for dogs with ClinL be co-infected with *E. canis* compared with healthy canine controls (CI: 1.5--106.0, *P* = 0.022) \[[@CR6]\]. A previous 3-year longitudinal study, evaluating *E. canis* and *L*. *infantum* co-infection in naturally exposed dogs, found that *E. canis* infection preceded *L*. *infantum* infection in dogs with dual infections, thus suggesting that *E. canis* could contribute in the establishment of ClinL \[[@CR7]\]. Interestingly, a recent study by Baxarias et al. \[[@CR5]\] from Catalonia (Spain) found that dogs with ClinL were four times more likely to be seropositive for *Rickettsia conorii* and 14 times most likely to be seropositive for *A. phagocytophilum* compared with healthy controls, but they did not found an association between ClinL and *E. canis* seroreactivity. This discrepancy probably reflects the different prevalence of these pathogens in Cyprus and other Mediterranean areas in comparison to Catalonia.

The seroprevalence of the various VBP in this specific canine population of 134 dogs from the area of Paphos, Cyprus, revealed a strikingly high seroreactivity to *E. canis*/*E*. *ewingii* (23%) and *anti-A*. *phagocytophilum*/*A*. *platys* (13%) antibodies compared to other studies from Mediterranean countries using a similar in-house ELISA kit as the one utilised in this study \[[@CR8]--[@CR10]\]. If quantitative ELISA or IFAT with higher sensitivity, compared to the in-house kit, were used in this study, then seroprevalences of the VBP could have been even higher than these reported \[[@CR11]\]. The area of Paphos, Cyprus, may be Lyme disease free as no anti-*B*. *burgdorferi* antibodies were detected in any of the dogs tested in this study, and the tick vectors that transmit this pathogen, including *Ixodes Ricinus*, have not yet been identified in Cyprus \[[@CR12]\]. In two dogs (1%) antigens for *D*. *immitis* were detected but PCR failed to confirm this infection and instead an infection with *A. reconditum* was identified for both cases. These results may indicate that the dogs had dual infection with both *D*. *immitis* and *A. reconditum*, and the negative PCR for *D*. *immitis* was as a result of low level microfilaraemia. However, false positive *D*. *immitis* results cannot be ruled out entirely especially in light of a recent study from Cyprus in which, using a modified Knott's testing for morphological identification of microfilariae in a total of 200 healthy dogs which did not receive any kind of heartworm prevention, only *A. reconditum* was identified in 9 dogs (4.5%) and no *D*. *immitis* was found \[[@CR13]\].

Conclusions {#Sec4}
===========

It was demonstrated that dogs with ClinL are three times more likely to be exposed to *E. canis*/*E. ewingii* than clinically healthy control dogs in Paphos, Cyprus. Furthermore, dogs from this area have a high seroreactivity to *E. canis*/*E*. *ewingii* and *A*. *phagocytophilum*/*A*. *platys* while they are *B*. *burgdorferi* free.

Methods {#Sec5}
=======

Study design, site and populations {#Sec6}
----------------------------------

The samples used for this serology study were collected under the frame of a previous case-control study design \[[@CR6]\]. All samples were collected from canine clinical cases presented to a small animal veterinary hospital in Paphos, Cyprus from April 2013 until March 2014. That area was selected since there are high numbers of CanL \[[@CR14]\] and various canine VBP have been reported \[[@CR15], [@CR16]\].

The exact recruiting criteria and the demographic characteristics recorded can be found in the previously published study \[[@CR6]\]. Briefly, the dogs that had ClinL were naturally infected and matched with clinically healthy control dogs in-terms of breed, sex, age, living in the same geographical area as well as ideally lifestyle and ectoparasitic prevention use.

Laboratory tests {#Sec7}
----------------

Approximately 1--2 ml of surplus serum collected in plain tubes and stored at − 20 °C until laboratory processing at the Diagnostic Laboratories of the Royal Veterinary College, London, UK.

A commercial in-clinic patient-side SNAP® 4Dx® Plus test kit (IDEXX Laboratories, Inc., Westbrook, Maine, USA) was used for the simultaneous detection of antibodies against *E. canis*/*E. ewingii*, *A. phagocytophilum*/*A. platys*, and *B. burgdorferi*, as well as antigens for *D. immitis*, following manufacturer's instructions. This ELISA kit utilises bi-directional flow of sample and automatic, sequential flow of wash solution and enzyme substrate. For *E. canis* it detects antibodies to the proteins p30 and p30--1, and for *E*. *ewingii* antibodies for p28 protein. For *A*. *phagocytophilum*/*A*. *platys* the assay detects antibodies against a peptide from the MSP2/p44 major surface protein and the C~6~ peptide is used for the detection of antibodies to a surface lipoprotein of *B*. *burgdorferi*. The assay detects antigens produced primarily from the uterus of female *D. immitis* (IDEXX Laboratories, Inc.).

Blood extracted DNA was submitted to IDEXX Laboratories, Ludwigsburg, Germany from all the cases that yielded positive antigens for *D. immitis* for further microfilaria specification using PCR specific assays for *D*. *immitis*, *Dirofilaria repens*, *Acanthocheilonema reconditum* and *Acanthocheilonema dracunculoides*. Additionally all samples underwent *L*. *infantum* serology \[[@CR17]\], qPCRs for *Leishmania* spp. \[[@CR18]\], *Babesia* spp. \[[@CR19]\], "*Candidatus* Mycoplasma haematoparvum" and *Mycoplasma haemocanis* \[[@CR20]\] as well as conventional PCR assays for *Ehrlichia/Anaplasma* spp. \[[@CR21]\] and *Hepatozoon* spp. \[[@CR22]\] under the framework of a previously published study \[[@CR6]\].

Data analysis {#Sec8}
-------------

The sample size was previously calculated \[[@CR6]\] and analyses were performed using SPSS for Windows (version 25.0; SPSS Inc., Chicago IL, USA). A univariable analysis was initially performed to see how each of the explanatory variables was associated with ClinL using Pearson's Chi-square test for categorical explanatory variables (breed, sex, lifestyle, ectoparasitic prevention, positivity for *A. phagocytophilum*/*A. platys*, positivity for *B. burgdorferi*, positivity for *E. canis*/*E*. *ewingii*, and positivity for *D. immitis*), and the two-sample t-test or Mann-Whitney U test for continuous variables (age). Any variables that showed a trend towards significant association with ClinL (*P-*value \< 0.1) were selected for entry into a multivariable logistic regression. A stepwise selection procedure was used to determine the final model (criteria for entry *P-*value ≤0.05 and for removal *P-*value \> 0.1).

Additionally, structural equation modelling (SEM) was performed reflecting the hypothesise mechanisms that may be associated with ClinL and other VBP exposure statuses in dogs: (a) causal effects of host characteristics, and (b) pathogen interrelationships, using a method previously described \[[@CR6]\].
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**Additional file 1: Table S1.** Raw datasets with signalment and test results per case enrolled.
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